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Objective Trans-cultural diabetes nutrition algorithm 
(tDNA) was created by international task force and 
culturally customized for Malaysian population. This study 
was designed to evaluate its effectiveness versus usual 
diabetes care in primary care settings.
Research design and methods We randomized 230 
patients with overweight/obesity, type 2 diabetes, and 
glycated hemoglobin (A1c) 7%–11% to receive usual care 
(UC) or UC with tDNA for 6 months. The tDNA intervention 
consisted of structured low-calorie meal plan, diabetes-
specific meal replacements, and increased physical 
activity. Participants were counseled either through 
motivational interviewing (tDNA-MI) or conventional 
counseling (tDNA-CC). The UC group received standard 
dietary and exercise advice through conventional 
counseling. All patients were followed for another 6 
months after intervention.
Results At 6 months, A1c decreased significantly in tDNA-
MI (−1.1±0.1%, p<0.001) and tDNA-CC (−0.5±0.1%, 
p=0.001) but not in UC (−0.2±0.1%, p=NS). Body weight 
decreased significantly in tDNA-MI (−6.9±1.3 kg, p<0.001) 
and tDNA-CC (−5.3±1.2 kg, p<0.001) but not in UC 
(−0.8±0.5 kg, p=NS). tDNA-MI patients had significantly 
lower fasting plasma glucose (tDNA-MI: −1.1±0.3 
mmol/L, p<0.001; tDNA-CC: −0.6±0.3 mmol/L, p=NS; 
UC: 0.1±0.3 mmol/L, p=NS) and systolic blood pressure 
(tDNA-MI: −9±2 mm Hg, p<0.001; tDNA-CC: −9±2 mm 
Hg, p=0.001; UC: −1±2 mm Hg, p=NS). At 1 year, tDNA-MI 
patients maintained significant reduction in A1c (tDNA-MI: 
−0.5±0.2%, p=0.006 vs tDNA-CC: 0.1±0.2%, p=NS and 
UC: 0.02±0.01%, p=NS) and significant weight loss (tDNA-
MI: −5.8±1.3 kg, p<0.001 vs tDNA-CC: −3.3±1.2 kg, 
p=NS and UC: 0.5±0.6 kg, p=NS).
Conclusions Structured lifestyle intervention through 
culturally adapted nutrition algorithm and motivational 
interviewing significantly improved diabetes control and 
body weight in primary care setting.
InTROduCTIOn
One of the major contributors to the rise in 
the global prevalence of pre-diabetes and 
type 2 diabetes is overweight and obesity. 
Overweight/obesity increases insulin resist-
ance and glucose intolerance, rendering type 
2 diabetes in patients with overweight/obesity 
more difficult to treat, non-pharmacologically 
or pharmacologically.1 2 Weight loss of at least 
5%–10% in patients with overweight/obesity 
and type 2 diabetes confers significant benefit 
in terms of decreasing insulin resistance and 
improving glycemic control, dyslipidemia 
and blood pressure.3 Effective implemen-
tation of medical nutrition therapy (MNT) 
with diabetes-specific therapeutic diets also 
improves glycemic control and risk for type 
2 diabetes complications.4 Therefore, based 
on an expanding and compelling evidence 
significance of this study
What is already known about this subject?
 ► Medical nutrition therapy (MNT) is effective for 
weight loss and improves glycemic control in type 
2 diabetes.
What are the new findings?
 ► Culturally-adapted, structured lifestyle intervention 
that includes MNT, physical activity, and 
motivational interviewing significantly improved 
weight loss and metabolic control in patients with 
overweight/obesity and type 2 diabetes.
How might these results change the focus of 
research or clinical practice?
 ► Providing a structured lifestyle intervention can help 
patients simplify the decision-making process and 
make dietary changes easier to follow.
 ► Incorporating behavioral counseling such as 
motivational interviewing as part of a structured 
lifestyle intervention can further enhance adherence 
and lead to significantly better metabolic outcomes.
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linking healthy lifestyle interventions with clinical benefit 
in type 2 diabetes, an international group of diabetes and 
nutrition experts developed the trans-cultural diabetes 
nutrition algorithm (tDNA) as a practical tool to opti-
mize care centered on cultural, ethnic, and geographic 
adaptations.5
Malaysia has a rising prevalence of type 2 diabetes 
affecting 17.5% of the adult population,6 with only 
a third of patients achieving the glycemic target of 
glycated hemoglobin A1c (A1c) <7.0%.7 8 The rise in type 
2 diabetes prevalence parallels the increasing overweight 
and obesity prevalence among Malaysians. The National 
Diabetes Registry 2009–2012 demonstrated that 83.4% 
of Malaysian patients with type 2 diabetes were, in fact, 
obese9 and 75% had abdominal obesity.10 Moreover, in 
Malaysia, only 16.4% of patients adhered to the dietary 
regimen provided by dietitians.11
The tDNA template was adapted for a Malaysian 
application, taking into account cultural differences in 
lifestyle, including healthy eating patterns, and genetic 
factors.12 The Malaysian tDNA recommends MNT as 
an integral component of glycemic control in type 2 
diabetes. Patients should receive personalized nutri-
tion counseling from dietitians, targeting weight loss 
of 5%–10% in 6 months, use of meal replacements to 
reduce total calorie intake, increased physical activity, 
and enhanced support to motivate patients so they can 
adhere with MNT recommendations. The Malaysian 
tDNA was configured as a structured lifestyle interven-
tion toolkit, consisting of meal plans, physical activity 
prescriptions, and general nutrition information, and 
then delivered using validated behavioral theories to 
promote adherence. This study aims to demonstrate the 
effectiveness of the Malaysian tDNA compared with usual 
care (UC) in patients with overweight/obesity and type 2 
diabetes in the primary care setting.
ReseaRCH desIgn and meTHOds
study design
This study was a randomized, open-label, clinical trial 
conducted with 6 months’ intervention and 6 months’ 
passive follow-up among patients with overweight/
obesity and type 2 diabetes. The study site was a primary 
care clinic in Seremban town, Negeri Sembilan. Ethical 
approval was obtained from the institutional review 
committee (IMU-R-134/2014) and from the National 
Medical Research Registry, Ministry of Health Malaysia 
(NMRR-14-1042-19455). Informed consent was obtained 
from all patients before screening and at enrollment, 
consistent with the Helsinki Declaration and the guide-
lines of the institutional review committee.
Participants
The clinic's register of patients with type 2 diabetes was 
reviewed and those who did not fit the age criteria were 
omitted from the attained list. Thereafter, medical records 
were assessed for further eligibility for recruitment. 
Contact details of patients who fulfilled the selection 
criteria were obtained. Patients were contacted through 
phone for verbal consent after an explanation on the 
study objectives and procedures was given. Patients who 
expressed interest to participate in the study were sched-
uled to come to the clinic. At the clinic, patients were 
provided with the information sheet regarding the trial in 
dual language (Malay and English) and written consent 
was obtained. Patients were recruited if they were male or 
female, aged 30–65 years, with body mass index (BMI) of 
>23 kg/m², and type 2 diabetes with A1c levels 7%–11%, 
not treated with insulin. Pharmacotherapy for type 2 
diabetes must have been unchanged in the last 3 months. 
Patients were excluded if they were pregnant or nursing, 
and had a history of serious diabetes-related complica-
tions or had a severe illness.
Randomization
Patients were randomized to receive UC or a structured 
lifestyle intervention based on the Malaysian tDNA 
using a random allocation software.13 Patients in the 
tDNA group were further randomized to receive either 
counseling with motivational interviewing (tDNA-MI) 
or conventional counseling (tDNA-CC) techniques to 
promote adherence with lifestyle recommendations. All 
study patients were required to complete a 2-week run-in 
period, which included successful self-monitoring of 
eating patterns and physical activity, as well as willingness 
to adhere to the study procedures.
Intervention
Structured lifestyle intervention
Patients in the tDNA intervention group underwent an 
initial risk stratification checklist and were prescribed 
MNT consisting of a structured low-calorie meal plan 
(1200 or 1500 kcal/day) using normal foods, incorpo-
ration of one or two diabetes-specific formula servings 
(Glucerna SR, Abbott Nutrition, USA) as meal replace-
ments according to the tDNA protocol and provided free 
of charge, and a physical activity prescription of at least 
150 min per week. Patients received education using the 
tDNA toolkit and consisting of a flip chart on healthy 
eating, 14-day meal plans, and culturally adapted infor-
mation on physical activity and exercise.
The tDNA-MI subgroup received counseling that 
incorporated motivational interviewing principles.14 
Motivational interviewing is directive, with a goal of elic-
iting self-motivational statements and behavioral change 
in addition to creating discrepancy to enhance motiva-
tion for positive change.14 The principles of motivational 
interviewing include expressing empathy through reflec-
tive listening, developing discrepancy between patients’ 
goals or values and their current behavior, avoiding argu-
ment and direct confrontation, adjusting to patient resis-
tance, and supporting self-efficacy and optimism.14 The 
tDNA-CC subgroup received conventional counseling 
techniques that focused on empathetic listening, educa-
tion, persuasion, and encouragement.
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Usual care
The UC comparator group followed the clinical care 
pathway of the Malaysian Clinical Practice Guidelines for 
Type 2 Diabetes Mellitus (2009) and received advice to 
follow a conventional low-calorie diet plan (1200 or 1500 
kcal/day) using normal foods with standard diabetes 
support and lifestyle education. Dietary counseling was 
conducted by the dietitian based on individualized care 
using conventional counseling techniques to facilitate 
positive behavioral change toward weight loss.
Follow-up
All patients were followed up at 3 and 6 months’ after 
termination of the intervention. During this phase, 
patients were required to keep a diary of food intakes and 
physical activities on a weekly basis. This follow-up phase 
focused on patients’ self-adherences to lifestyle change 
and effect on weight and A1c control after the interven-
tion has been terminated.
Frequency of contact
Patients in the tDNA-MI and tDNA-CC were followed up 
monthly by the dietitian and physician during the inter-
vention phase and subsequently every 3 months during 
the follow-up phase. Patients in the UC group were 
followed up 3 monthly throughout the study duration by 
the dietitian and physician. All patients were contacted 
via telephone only to remind them of their scheduled 
clinic visits and also to reschedule missed appointments.
Primary and secondary outcomes
The primary outcomes of the study were changes in A1c, 
while the secondary outcome measures were changes in 
weight, BMI, waist circumference, percentage body fat, 
fasting plasma glucose (FPG), systolic and diastolic blood 
pressure, blood lipid levels, and high-sensitivity C reac-
tive protein (hsCRP).
measurements
Weight was measured using a digital weighing scale 
(Tanita HD-319, Tanita, Japan) and height was measured 
using a stadiometer (SECA, Hamburg, Germany). BMI 
was calculated using the obtained weight and height 
measurements. Waist circumference was taken at the 
midpoint between the lower margin of the last palpable 
rib and the top of the iliac crest with a measuring tape. 
Body fat was measured using a bioelectrical impedance 
analysis machine (Omron Karada Scan HBF-356, Omron 
Healthcare, Japan). Seated blood pressure was measured 
in duplicate, using an automated device after a 5 min rest. 
Prior to measurement, the patient’s blood pressure was 
measured in both arms to determine which arm should 
be used for future measurements. The arm that gave 
higher systolic reading was used for all future testing.
Blood was withdrawn from patients after an overnight 
fast of 10–12 hours and analyzed using automated proce-
dures. Blood measurements included A1c, FPG, total 
cholesterol, low-density lipoprotein-cholesterol (LDL-C), 
high-density lipoprotein-cholesterol, triglyceride, and 
hsCRP.
Food intake was recorded for 3 days (2 weekdays and 
1 weekend, consecutively) by patients using household 
measurements. Colored food albums with photographs 
of actual serving sizes were used to help quantify the food 
portions consumed. Written instructions with example of 
a 1-day food record were given to all patients. Food records 
were reviewed by the dietitian during face-to-face patient 
encounters. Patients in the tDNA groups kept monthly 
food records during the intervention phase and subse-
quently every 3 monthly records during the follow-up 
phase. Patients in the UC group kept 3 monthly food 
records throughout the study. The nutrient content of 
each food was analyzed using Nutritionist Pro computer 
software (V.5.1.0, Axxya Systems, USA), primarily based 
on the nutrient composition of Malaysian foods.15
Physical activity level was assessed every 3 months using 
the International Physical Activity Questionnaire-Short 
Form validated for Malaysians. Patients also recorded a 
daily exercise diary. A medicine profile questionnaire was 
developed and implemented for this study. This ques-
tionnaire consisted of the type of medicines, dosage, 
frequency, and any remarks pertaining to the intake of 
medicines.
Patients were required to self-report the frequency and 
amount of diabetes-specific formulas consumed as meal 
replacements on a daily basis. Patients were also asked 
to return the scoops from each can of the formulas. The 
adherence rate was calculated as percentage of the actual 
consumption over expected consumption at each month.
Power and sample size
The sample size was calculated based on published data 
from the Look AHEAD (Action for Health in Diabetes) 
study results for A1c changes.16 The differences between 
the A1c means calculated was 0.4% between the intensive 
lifestyle intervention and diabetes support and education 
groups at 80% power with a type 1 error of 5% (α=5%). 
With an assumed SD of 1 from the Look AHEAD study, 
the sample size obtained was 115 patients per arm inclu-
sive of 15% dropout rate. Hence, the total sample size 
needed for this study was 230 patients (115 patients 
receiving UC; 115 patients receiving tDNA care).
statistical analysis
Statistical analysis was done using the Statistical Package 
for Social Sciences (SPSS) V.22 software. Descrip-
tive statistics (mean, SD, median, IQR, SE, frequency, 
and percentage of patients) were used to describe the 
baseline data. The parametric data were presented as 
mean±SD, where comparisons between groups were done 
using one-way analysis of variance (ANOVA) for contin-
uous variables. The non-parametric data were presented 
as median±IQR, where comparisons between groups 
were done using Kruskal-Wallis test for continuous data. 
The χ² tests were used for comparison between groups 
for categorical data.
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Changes in outcomes were computed from baseline 
to 6 or 12 months of the intervention period. The abso-
lute changes and percentage changes of measures were 
computed as below:
A. Absolute change=mean at 6 or 12 months – mean at 
baseline
B.  
Percent change = (mean at 6 or 12 months−mean at baseline)×100mean at baseline  
Comparisons of changes in outcomes within groups 
were made using the generalized estimating equation 
test for intention-to-treat analysis, and comparisons of 
changes in outcomes between groups were made using 
the one-way ANOVA and Kruskal-Wallis tests for per-pro-
tocol analysis. The post-hoc Sidak test was used to report 
multiple comparisons within groups. . All p values of less 
than 0.05 were statistically significant.
The benefit of modest weight loss was examined 
between percentage weight loss categories and absolute 
change in A1c level. Patients were categorized based on 
their weight changes from baseline to 6 months of inter-
vention: gained >2%, remained stable weight (±2%), lost 
>2% to ≤5%, lost >5% to ≤8%, and lost >8%. These cate-
gories were selected in order to allow adequate propor-
tions of patients for analysis. Mean and SEM (±2 SE) were 
plotted to illustrate significant interactions, and separate 
linear regression models determined significant relation-
ships between the tested variables.
ResulTs
Baseline data
Figure 1 shows the trial enrollment, in which out of the 
11 431 patients listed in the clinic register, 473 (41.4%) 
were found to be eligible for clinic visits to confirm 
eligibility. Only 244 attended the clinic screening; 229 
(48.4%) did not consent or come in for the appointment. 
Of these, 14 individuals were ineligible because they 
did not meet the inclusion criteria for A1c. Hence, 230 
(94.2%) were ultimately randomized: 115 were assigned 
to the tDNA intervention group (58 in tDNA-MI; 57 in 
tDNA-CC) and 115 to the UC group.
The median and IQR for the age of study patients were 
55±8 years for both tDNA-MI and tDNA-CC groups and 
54±8 years for UC groups. The majority of patients were 
female in the tDNA groups compared with the UC group 
(tDNA-MI 67.2%; tDNA-CC 87.4%; and UC 48.7%), while 
all groups had similar ratios of patients from the three 
main Malaysian ethnicities (Malays 14%, Chinese 28%, 
Indians 58%). This is in line with type 2 diabetes being 
more prevalent among Malaysian Indians in the country. 
More than 90% of the patients were married.
At baseline, UC patients had higher median values for 
height and lower median values for body fat percentage 
due to more male patients being randomized into this 
group compared with tDNA groups (table 1). The median 
values for FPG was significantly (p<0.001) lower in the 
tDNA-MI patients (6.9±1.8 mmol/L) compared with 
tDNA-CC (7.6±2.9 mmol/L) and UC (7.8±2.7 mmol/L). 
All other biochemical data including A1c, blood pres-
sure, energy intake, and exercise duration per week were 
not significantly different in the groups at baseline.
The median duration of patients having type 2 diabetes 
was significantly (p=0.047) lower in the tDNA-CC group 
(6±3 years) than in tDNA-MI (8±5 years) and UC (7±5 
years) groups. However, there was no significant differ-
ence in comorbidities in the three groups. Hypertension 
and dyslipidemia represented the major comorbid condi-
tions in the three groups (34.5% tDNA-MI, 35.1% tDNA-
CC, and 35.7% UC). Similarly, there was no significant 
variance in pharmacologic therapy among the patients. 
Overall, they were treated with oral antidiabetic agents: 
biguanides only (n=214), sulfonylureas only (n=183), or 
combination of the two (n=15). Majority were also taking 
antihypertensive drugs (n=360), statins (n=164), and 
fibrates (n=7).
Changes at 6 months’ intervention phase
The adherence rates of the tDNA-MI and tDNA-CC 
patients to the meal replacements were comparable 
(tDNA-MI 94.8%±5.7% and tDNA-CC 96.2%±5.1%; 
p=0.217). After 6 months of receiving either tDNA inter-
vention or UC, patients in the tDNA groups showed 
significant lowering of A1c, which was the primary 
outcome of the study. The A1c improved significantly for 
patients in both the tDNA intervention groups, with the 
tDNA-MI patients achieving a greater lowering of A1c 
values (−1.1±0.1%, p<0.001) than the tDNA-CC patients 
(−0.5±0.1%, p<0.001), as shown in table 2. The A1c 
values in the UC group had no significant changes from 
baseline.
The body weight and BMI also reduced significantly 
in both the tDNA intervention groups, where tDNA-MI 
group achieved a greater (mean±SE) weight loss of 
6.9±1.3 kg (p<0.001), while patients in the tDNA-CC 
group achieved weight loss of 5.3±1.2 kg (p<0.001). Simi-
larly, the magnitude of loss was greater in the tDNA-MI 
group for BMI than in the tDNA-CC group. The UC 
group did not show any significant changes in weight, 
BMI, and A1c during the first 6 months.
Waist circumference (tDNA-MI: −4.0±1.1 cm, p=0.002; 
tDNA-CC: −2.7±1.0 cm, p=0.062; UC: −0.5±0.5 cm, 
p=0.960) and FPG (tDNA-MI: −1.1±0.3 mmol/L, 
p=0.011; tDNA-CC: −0.6±0.3 mmol/L, p=0.632; UC: 
0.1±0.3 mmol/L, p=1.000) decreased significantly in the 
tDNA-MI group than in the tDNA-CC and UC groups.
Systolic blood pressure also decreased significantly 
in the tDNA-MI (−9±2 mm Hg, p<0.001) and tDNA-CC 
(−9±2 mm Hg, p=0.001), but not in the UC patients 
(−1±2 mm Hg, p=1.000). Diastolic blood pressure, 
however, was significantly lowered in tDNA-CC patients 
(−6±2 mm Hg, p=0.008), but not in the tDNA-MI 
(−3±1 mm Hg, p=0.442) and UC groups (−1±1 mm Hg, 
p=0.980).
At 6 months, the hsCRP did not change for any of 
the groups. In the UC group, total cholesterol (UC: 
−0.3±0.1 mmol/L, p<0.001; tDNA-MI: −0.2±0.1 mmol/L, 
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Figure 1 Patients’ retention rates. tDNA-CC, trans-cultural diabetes nutrition algorithm-conventional counseling; tDNA-MI, 
trans-cultural diabetes nutrition algorithm-motivational interviewing.
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Table 1 Baseline characteristics of patients (n=230)
tDNA-MI (n=58) tDNA-CC (n=57) UC (n=115) p Value
Anthropometry
  Weight (kg) 78.3±20.9 74.6±16.0 75.8±18.6 0.218
  Height (cm) 159.6±15.1 157.0±7.5 163.6±12.4 0.005*
  Body mass index (kg/m²) 30.7±8.2 29.4±7.3 28.9±6.3 0.171
  Waist circumference (cm)† 102.9±14.5 101.8±10.7 100.7±11.7 0.546
Body composition
  Body fat (%) 38.3±10.2 39.3±7.1 35.4±10.0 <0.001*
Biochemical
  A1c (%) 7.7±1.1 7.7±1.4 7.9±1.3 0.368
  A1c (mmol/mol) 61±12 61±15 63±14 0.368
  FPG (mmol/L) 6.9±1.8 7.6±2.9 7.8±2.7 <0.001*
  Total cholesterol (mmol/L)† 4.7±0.8 4.9±1.0 4.9±0.9 0.485
  LDL-C (mmol/L)† 2.72±0.76 2.94±0.88 2.91±0.77 0.247
  HDL-C (mmol/L) 1.29±0.37 1.19±0.22 1.19±0.28 0.126
  Triglyceride (mmol/L) 1.45±0.75 1.46±0.89 1.52±0.73 0.340
  hsCRP (mg/L) 5.2±6.5 5.6±9.0 3.3±6.2 0.103
Blood pressure
  Systolic (mm Hg) 132±20 136±20 134±24 0.697
  Diastolic (mm Hg)† 77±9 79±11 80±11 0.252
Dietary intake and exercise
  Energy intake (kcal/day)† 1665±408 1588±304 1733±486 0.112
  Exercise (min/week) 114±131 80±158 55±155 0.077
All data expressed as median±IQR.
*Significant difference between groups at p<0.05 by one-way analysis of variance for parametric data and by Kruskal-Wallis for non-
parametric data.
†Data presented as mean±SD.
A1c, glycated hemoglobin; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein-cholesterol; hsCRP, high-sensitivity C reactive 
protein; LDL-C, low-density lipoprotein-cholesterol; tDNA-CC, trans-cultural diabetes nutrition algorithm-conventional counseling; tDNA-MI; 
trans-cultural diabetes nutrition algorithm-motivational interviewing; UC, usual care.
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p=0.599; tDNA-CC:−0.2±0.1 mmol/L, p=0.493) and LDL-C 
were lowered significantly (UC: −0.26±0.07 mmol/L, 
p=0.005; tDNA-MI: −0.08±0.08 mmol/L, p=0.980; tDNA-
CC:−0.18±0.09 mmol/L, p=0.386) due to an increase in 
statin dose and change to stronger medication in the 
majority, that is, 56.5% of patients, while only 38.5% of 
patients in the tDNA groups had their lipid-lowering 
medication adjusted.
Patients in the tDNA groups ate significantly fewer 
calories (tDNA-MI: −574±43 kcal/day, p<0.001; tDNA-
CC: −458±47 kcal/day, p<0.001) than patients in the UC 
group (−171±46 kcal/day, p=0.002) at 6 months. There 
was a concomitant decrease in carbohydrate, protein, 
and fat intake, with the decrease in energy intake in the 
tDNA patients with the exception that UC patients main-
tained their protein intake. Patients in tDNA-MI group 
also did longer duration of exercise (188±16 min/week, 
p<0.001) than patients in the tDNA-CC (149±24 min/
week, p=0.383) and UC groups (106±14 min/week, 
p=1.000) (table 3).
About 41.0% of tDNA-MI patients and 38.0% of 
tDNA-CC patients experienced symptomatic hypogly-
cemia at an average of two to four episodes in a month, 
which were resolved at once. They received diabetes 
medicine adjustments in addition to dietary treat-
ment of hypoglycemia. The use of oral diabetic agents 
decreased in more tDNA-MI (19.6%) than tDNA-CC 
patients (12.5%), while it increased for 37.4% of the 
UC patients.
Changes at follow-up
When patients were followed up, that is, 6 months 
after the intervention has stopped, the weight, BMI, 
and A1c of all groups increased (figure 2). However, 
tDNA-MI patients were able to maintain significant 
weight loss from their baseline but not for patients in 
tDNA-CC and UC groups (−5.8±1.3 kg vs −3.3±1.2 kg 
vs 0.5±0.6 kg, p<0.001, respectively). This corresponded 
to percentage weight loss of −4.6±0.5% in tDNA-MI, 
−1.2±0.5% in tDNA-CC, and 0.5%±0.3% in UC groups 
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Table 2 Changes in weight and metabolic measures after 6 months’ intervention phase (mean±SE)
tDNA (n=115)
UC (n=115) p ValuetDNA-MI (n=58) tDNA-CC (n=57)
Weight (kg)
  Baseline 82.8±2.6 75.9±1.8 78.1±1.3
  6 months 75.9±2.5 70.6±2.0 77.3±1.4
  Change −6.9±1.3 −5.3±1.2 −0.8±0.5
  p Value* <0.001† <0.001† 0.702 <0.001†‡
Body mass index (kg/m²)
  Baseline 31.8±0.9 30.5±0.6 29.6±0.4
  6 months 29.5±0.9 28.5±0.7 29.5±0.4
  Change −2.3±0.4 −2.0±0.4 −0.1±0.2
  p Value* <0.001† <0.001† 1.000 <0.001†§
Waist circumference (cm)
  Baseline 102.9±1.9 101.8±1.4 100.7±1.1
  6 months 98.9±1.8 99.1±1.6 100.2±1.2
  Change −4.0±1.1 −2.7±1.0 −0.5±0.5
  p Value* 0.002† 0.062 0.960 <0.001†‡
Body fat (%)
  Baseline 37.3±0.9 39.1±0.7 34.9±0.6
  6 months 36.0±0.9 37.7±0.8 35.4±0.6
  Change −1.3±0.4 −1.5±0.5 0.4±0.3
  p Value* 0.002† 0.017† 0.742 <0.001†§
A1c (%)
  Baseline 8.0±0.1 8.1±0.1 8.1±0.1
  6 months 6.9±0.1 7.6±0.2 7.9±0.1
  Change −1.1±0.1 −0.5±0.1 −0.2±0.1
  p Value* <0.001† 0.001† 0.231 <0.001†§
A1c (mmol/mol)
  Baseline 64±1 65±1 65±1
  6 months 52±1 59±2.0 63±1
  Change −12±1 −6±1 −2±1
  p Value* <0.001† 0.001† 0.231 <0.001†§
FPG (mmol/L)
  Baseline 7.4±0.3 8.3±0.4 8.2±0.2
  6 months 6.3±0.2 7.7±0.4 8.2±0.3
  Change −1.1±0.3 −0.6±0.3 0.1±0.3
  p Value* 0.011† 0.632 1.000 0.027†§
SBP (mm Hg)
  Baseline 134±2 136±2 137±2
  6 months 124±2 127±2 136±2
  Change −9±2 −9±2 −1±2
  p Value* <0.001† 0.001† 1.000 0.003†‡
DBP (mm Hg)
  Baseline 77±1 79±1 80±1
  6 months 74±1 73±2 79±1
  Change −3±1 −6±2 −1±1
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tDNA (n=115)
UC (n=115) p ValuetDNA-MI (n=58) tDNA-CC (n=57)
  p Value* 0.442 0.008† 0.980 0.013†§
Total cholesterol (mmol/L)
  Baseline 4.7±0.1 4.9±0.1 4.9±0.1
  6 months 4.6±0.1 4.7±0.1 4.6±0.1
  Change −0.2±0.1 −0.2±0.1 −0.3±0.1
  p Value* 0.599 0.493 0.001† 0.741‡
LDL-C (mmol/L)
  Baseline 2.72±0.10 2.94±0.12 2.91±0.07
  6 months 2.63±0.10 2.76±0.12 2.65±0.08
  Change −0.08±0.08 −0.18±0.09 −0.26±0.07
  p Value* 0.980 0.386 0.005† 0.565§
HDL-C (mmol/L)
  Baseline 1.31±0.04 1.23±0.04 1.22±0.02
  6 months 1.32±0.04 1.28±0.05 1.22±0.04
  Change 0.01±0.03 0.05±0.04 0.002±0.03
  p Value* 1.000 0.888 1.000 0.484§
Triglyceride (mmol/L)
  Baseline 1.56±0.09 1.76±0.16 1.77±0.09
  6 months 1.35±0.07 1.51±0.10 1.64±0.08
  Change −0.21±0.08 −0.25±0.16 −0.14±0.09
  p Value* 0.105 0.753 0.797 0.855§
hsCRP (mg/L)
  Baseline 7.3±1.0 7.4±0.9 5.7±0.6
  6 months 5.6±0.8 7.0±1.1 4.9±0.5
  Change −1.7±0.8 −0.4±0.7 −0.8±0.5
  p Value* 0.078 0.933 0.300 0.092§
All data expressed as (mean±SE) for absolute change in measures.
*p Values measure changes within groups by generalized estimating equations for intention-to-treat analysis based on post-hoc Sidak test 
for multiple comparisons over time.
†Significant changes from baseline at p<0.05.
‡p Values measure absolute change in measures between groups by one-way analysis of variance for per-protocol analysis for tDNA-MI 
(n=51), tDNA-CC (n=40), and UC (n=101).
§p Values measure absolute change in measures between groups by Kruskal-Wallis for per-protocol analysis for tDNA-MI (n=51), tDNA-CC 
(n=40), and UC (n=101).
A1c, glycated hemoglobin; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein-cholesterol; hsCRP, 
high-sensitivity C reactive protein; LDL-C, low-density lipoprotein-cholesterol; SBP, systolic blood pressure; tDNA-CC, trans-cultural diabetes 
nutrition algorithm-conventional counseling;  tDNA-MI, transcultural diabetes nutrition algorithm-motivational interviewing; UC, usual care.
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(p<0.001), respectively (figure 2). The tDNA-MI group 
also maintained a significant reduction of A1c from 
baseline during the follow-up phase, but tDNA-CC 
and UC patients had A1c values returning to baseline 
(−0.5±0.2% vs 0.1±0.1% vs 0.1±0.1%, p=0.007, respec-
tively; figure 2).
Weight changes and a1c
The benefit of modest weight loss on A1c was examined 
between percentage weight loss and change in A1c for the 
entire study population (n=230) (figure 3). There was a 
significant interaction between the amount of weight loss 
and A1c. The results showed a significant relationship 
of modest weight loss (as low as 2%–5% from baseline) 
with reduction in A1c by −0.5% (p<0.001). Furthermore, 
weight loss of 5%–8% was associated with a further drop 
in A1c by −1.0% (p<0.001).
COnClusIOns
The present results show that MNT based on the Malay-
sian tDNA and a customized pragmatic toolkit provides 
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Table 3 Changes in dietary intake and exercise duration after 6 months’ intervention phase (mean±SE)
tDNA (n=115)
UC (n=115) p ValuetDNA-MI (n=58) tDNA-CC (n=57)
Energy (kcal/day)
  Baseline 1665±53 1588±40 1733±45
  6 months 1091±29 1130±37 1562±38
  Change −574±43 −458±47 −171±46
  p Value* <0.001† <0.001† 0.002† <0.001†‡
Carbohydrate (g/day)
  Baseline 224.3±7.5 213.6±5.7 234.0±6.3
  6 months 154.8±4.9 157.2±5.7 208.9±5.0
  Change −69.5±6.0 −56.4±6.5 −25.1±6.7
  p Value* <0.001† <0.001† 0.002† <0.001†‡
Protein (g/day)
  Baseline 74.3±2.8 70.6±2.2 72.6±1.9
  6 months 48.6±1.4 52.2±2.0 69.0±1.8
  Change −25.8±2.4 −18.5±2.6 −3.6±1.9
  p Value* <0.001† <0.001† 0.453 <0.001†‡
Fat (g/day)
  Baseline 52.9±2.3 50.4±2.0 56.4±1.9
  6 months 31.0±1.0 32.6±1.5 50.3±1.8
  Change −21.9±2.1 −17.8±2.3 −6.1±2.1
  p Value* <0.001† <0.001† 0.031† <0.001†‡
Exercise (min/week)
  Baseline 123±14 105±14 113±16
  6 months 188±16 149±24 106±14
  Change 66±14 45±23 −7±13
  p Value* <0.001† 0.383 1.000 <0.001†‡
All data expressed as (mean±SE) for absolute change in measures.
*p Values measure changes within groups by generalized estimating equations for intention-to-treat analysis based on post-hoc Sidak test 
for multiple comparisons over time.
†Significant changes from baseline at p<0.05.
‡p Values measure absolute change in measures between groups by Kruskal-Wallis for per-protocol analysis for tDNA-MI (n=51), tDNA-CC 
(n=40), and UC (n=101).
tDNA-CC, trans-cultural diabetes nutrition algorithm-conventional counseling; tDNA-MI, trans-cultural diabetes nutrition algorithm-
motivational interviewing; UC, usual care.
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a structured lifestyle approach achieving clinically signif-
icant weight loss and improved glycemic control in 
patients with overweight/obesity and type 2 diabetes. 
After 6 months, patients in the tDNA-MI group achieved 
an average weight loss of −5.8 kg (−5.2% change) of initial 
body weight, −3% drop in BMI, and significant reduc-
tions of body fat and waist circumference. The changes 
in body weight and composition were associated with a 
significant decrease in A1c of −0.8% and FPG by −5% in 
the intervention group. Patients in the tDNA groups also 
had significant lowering of systolic blood pressure by an 
average of −9.0 mm Hg (−6% change). The provision of 
structured meal plans with the use of meal replacements 
also led to higher decrease in energy intakes in the tDNA 
patients. The increased exercise minutes practiced by the 
tDNA-MI group possibly contributed to the higher drop 
in body weight as well.
Change in body weight in the present study was linearly 
correlated with A1c reduction, where modest weight 
loss of just 2%–5% was sufficient to produce significant 
improvement in A1c in these patients. Several meta-anal-
yses17 18 have reported an average weight reduction of 
5 kg or around 6% from baseline using lifestyle inter-
ventions with incorporation of meal replacements in 
patients with type 2 diabetes, compared with UC or brief 
diabetes education sessions. Terranova et al17 reported a 
pooled effect of A1c reduction of −0.29%, while Chen et 
al19 reported a significant reduction in A1c by −0.37%. 
Several other studies involving lifestyle interventions 
with the incorporation of meal replacements reported 
10 BMJ Open Diab Res Care 2017;5:e000384. doi:10.1136/bmjdrc-2016-000384
Figure 2 Graph of percentage weight change and 
absolute change in A1c with time (mean±SE). *Significant 
changes between groups from baseline at p<0.05 by one-
way analysis of variance. A1c, glycated hemoglobin; tDNA-
CC, trans-cultural diabetes nutrition algorithm-conventional 
counseling; tDNA-MI, trans-cultural diabetes nutrition 
algorithm-motivational interviewing. 
Figure 3 Graph of mean and SEM (mean±2 SE) between 
weight loss categories and change in glycated hemoglobin 
(A1c). *Significant association by regression analysis at 
p<0.05.
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weight losses of 2–4 kg in 1 year,20–23 with corresponding 
drops in A1c ranging from 0.1% to 0.8%. Hence, the 
magnitude of weight loss and A1c reduction achieved in 
this study is higher compared with several other similar 
studies conducted in diabetes populations using lifestyle 
interventions.
Cardiovascular risk reduction with structured lifestyle 
intervention may have been related to the significant 
reduction in waist circumference, blood pressure, and 
hyperglycemia in this study. Achieving a reduction in 
adiposity correlates with decreased insulin resistance and 
should be an essential therapeutic target.24 25 Evidence 
from the UKPDS studies have shown that reduction in 
blood pressure can significantly reduce microvascular 
complications by 37% and risk of stroke by 44%.26 
However, lipid profile changes could not be attributed to 
the tDNA intervention in this study since the majority of 
patients were on statin drugs and had optimal cholesterol 
levels at baseline. In addition, there were no changes in 
hsCRP, indicating the absence of any significant change 
in inflammatory responses, regardless of the intervention 
provided.
In the subsequent 6-month follow-up after the inter-
vention terminated, all groups regained some of their lost 
weight—a common observation after successful weight 
loss treatment—leading to the concomitant rise in A1c. 
The usual course of weight loss therapy shows that weight 
is quickly lost at first, and the point of greatest loss occurs 
6 months after beginning of treatment; then the weight 
is slowly regained until weight returns near the baseline 
level,27 as also demonstrated by this study. Several factors 
can lead to weight regain: changes in appetite-related 
hormones causing increased hunger and energy storage, 
and diet-induced lean weight loss causing decreased 
energy expenditures.28
One of the most significant findings of this study is 
the beneficial effects of using a counseling approach 
that incorporates motivational interviewing as part of a 
structured lifestyle intervention. tDNA-MI patients in the 
study showed significantly better outcomes in terms of 
weight, BMI, body composition, A1c, FPG, systolic blood 
pressure, reduced energy intake, and increased exer-
cise minutes during the 6 months’ intervention period. 
Moreover, patients receiving motivational interviewing 
maintained significantly lower body weight and A1c levels 
even 1 year after the intervention terminated. There is 
increasing evidence that the use of motivational inter-
viewing to assist weight loss program for type 2 diabetes 
can result in higher weight loss and maintenance of 
weight loss.29 Physicians applying the motivational inter-
viewing ‘spirit’ (such as collaboration) and motivational 
interviewing-consistent strategies (such as reflective 
statements) had patients with obesity who demonstrated 
significantly greater weight loss than with those physi-
cians not embedding the motivational interviewing spirit 
or using motivational interviewing-inconsistent behaviors 
(such as judging and confronting).30 A meta-analysis of 
six studies evaluated the effectiveness of motivational 
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interviewing on self-management in patients with type 2 
diabetes and reported that A1c was significantly lowered 
in the intervention groups at 6 months compared with 
control groups (weighted mean difference=−0.44, 95% CI 
−0.73 to −0.15, p=0.003).31
Providing a structured intervention was able to help 
individuals simplify the decision-making process and 
identify how to make changes, and in addition the use 
of meal replacements provided a strategy that enhanced 
dietary adherence.32 One meta-analysis found that the 
use of meal replacements increased both short-term and 
long-term average weight loss by about 2.5 kg, compared 
with prescription of a conventional reducing diet with 
the same calorie goals.33 In the Look AHEAD study, at 
1 year, meal replacements used as part of the compre-
hensive behavioral strategy were associated with an 
8.6% weight loss compared with a 0.7% weight loss in the 
control group receiving standard diabetes support and 
education.34 The use of meal replacements also assists 
weight maintenance or further weight loss in patients 
who lost at least 5% of body weight.35 Other factors 
contributing to the positive results seen in the patients 
in this study included frequent food diary and exercise 
self-monitoring. A review reported that self-monitoring 
in weight loss interventions was necessary to support 
behavior change for weight loss as it encourages the 
development of self-regulatory skills, such as evaluating 
and reinforcing progress made toward a particular 
behavior.36
In conclusion, culturally-adapted, structured lifestyle 
intervention that includes MNT, physical activity, and 
motivational interviewing significantly improves weight 
loss and metabolic control in patients with overweight/
obesity and type 2 diabetes.
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